Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest Article Swipe
Related Concepts
Peter J. Kudenchuk
,
Siobhan P. Brown
,
Mohamud Daya
,
Thomas D. Rea
,
Graham Nichol
,
Laurie J. Morrison
,
Brian G. Leroux
,
Christian Vaillancourt
,
Lynn Wittwer
,
Clifton W. Callaway
,
James Christenson
,
Debra Egan
,
Joseph P. Ornato
,
Myron L. Weisfeldt
,
Ian G. Stiell
,
Ahamed H. Idris
,
Tom P. Aufderheide
,
James V. Dunford
,
M. Riccardo Colella
,
Gary M. Vilke
,
Ashley Brienza
,
Patrice Desvigne‐Nickens
,
Pamela C. Gray
,
Randal Gray
,
Norman Seals
,
Ron Straight
,
Paul Dorian
·
YOU?
·
· 2016
· Open Access
·
· DOI: https://doi.org/10.1056/nejmoa1514204
· OA: W2330410310
YOU?
·
· 2016
· Open Access
·
· DOI: https://doi.org/10.1056/nejmoa1514204
· OA: W2330410310
Overall, neither amiodarone nor lidocaine resulted in a significantly higher rate of survival or favorable neurologic outcome than the rate with placebo among patients with out-of-hospital cardiac arrest due to initial shock-refractory ventricular fibrillation or pulseless ventricular tachycardia. (Funded by the National Heart, Lung, and Blood Institute and others; ClinicalTrials.gov number, NCT01401647.).
Related Topics
Finding more related topics…